Home
Clinical Trials
Hydroxychloroquine as a Stero...

Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis

Last Updated: 2025-09-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-30

Study Completion Date

2029-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sarcoidosis is a systemic granulomatous disease of unknown aetiology, mainly affecting the lungs and lymphatics. It affects people worldwide (incidence, 4.7-64/100000; prevalence, 1-36/100000/year). Although it is most often a benign acute or subacute condition, sarcoidosis may progress to a disabling chronic disease in 25% of the cases, with severe complications in about 5%, such as lung fibrosis, cardiac or neurosarcoidosis, defacing lupus pernio or blindness due to uveitis.

When indicated, corticosteroids (CS) are the mainstay of treatment. Due to the kinetics of granuloma resolution, the usual and quite 'dogmatic' duration of treatment is said to be one year, following four classical steps. The long-term use of CS is hindered by cumulative toxicity and efforts have to be made to taper them, as quickly as possible, to the lowest effective dose. A recent report mentioned 39% of the CS-treated patients requiring a steroid-sparing agent. Chloroquine (CQ) and hydroxychloroquine (HCQ) are anti-malarial drugs that have been used since the 1960's as steroidsparing agents on the basis of a landmark study by Siltzbach reporting their efficacy in 43 patients with skin and intrathoracic sarcoidosis. Subsequently, two small randomized controlled trials have shown significant and prolonged improvement on pulmonary symptoms. Only small case series/reports have shown CQ/HCQ efficacy on extra-pulmonary sarcoidosis with response rates ranging from 67 to 100%. Nevertheless, CQ/HCQ are daily used for skin, bone, and joint sarcoidosis, as well as hypercalcemia. Nowadays, HCQ is preferred over CQ because of a lower incidence of gastrointestinal and ocular adverse reactions, which can be minimized by close attention to the dosage and regular retinal examination. Its profile of safety is well-known since it has long been employed to treat systemic lupus erythematous or rheumatoid arthritis. Its action is thought to rely on its ability to accumulate in lysosomes of phagocytic cells, to affect antigen presentation and reduce pro-inflammatory cytokines. The investigator hypothesize that HCQ may be an efficacious add-on therapy for extra-pulmonary sarcoidosis leading to a significant steroid-sparing effect.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis

NCT05247554

Pulmonary Sarcoidosis

UNKNOWN PHASE3

Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients

NCT05084872

Mastocytosis

UNKNOWN PHASE2/PHASE3

"Randomized Controlled Trial Testing the Efficacy of Corticosteroid Therapy Versus Placebo in Fibrotic Hypersensitivity Pneumonitis"

NCT07210008

Hypersensitivity Pneumonitis

NOT_YET_RECRUITING PHASE3

Exploring the Immunology of Sarcoidosis

NCT04637165

Sarcoidosis

COMPLETED

Hydroxychloroquine Efficacy in Chronic Urticaria

NCT01073852

Chronic Urticaria

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoidosis, Pulmonary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hydroxychloroquine

prednisone (scheduled protocol) + hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period, then according to the treating the physician for an additional open period of 12 months)

Group Type EXPERIMENTAL

Hydroxychloroquine

Intervention Type DRUG

Hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period)

Placebo arm

prednisone (scheduled protocol) + placebo (1-2 tablets/day during a 12 months double blind placebocontrolled period, then the treatment is left to the physician's discretion until M24)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo during a 12 months double blind placebo-controlled period

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydroxychloroquine

Hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period)

Intervention Type DRUG

Placebo

Placebo during a 12 months double blind placebo-controlled period

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* at least 18 years of age
* pathologically proven sarcoidosis as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)/World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) criteria
* non severe ocular sarcoidosis requiring systemic treatment
* non severe skin sarcoidosis requiring systemic treatment
* non severe osseous sarcoidosis requiring systemic treatment
* non severe sarcoidosis with joint involvement requiring systemic treatment
* non severe sarcoidosis-related hypercalcemia requiring systemic treatment
* non severe peripheral nervous system sarcoidosis requiring systemic treatment
* non severe sarcoidosis-related non-severe Ear, Nose and Throat (ENT) involvement requiring systemic treatment
* symptomatic hypercalciuria \>200 mg/24h (24 h urine) OR

* \- \> 20 mg/mmol creatinine on urine sample
* \- \> 180 mg/g creatinine on urine sample
* signed informed consent
* affiliated to National French social security system

Exclusion Criteria

* severe sarcoidosis involvement requiring another immunosuppressant or anti-TNF antibody or methylprednisolone i.v. pulses
* previous (\<3 months before screening) or concurrent treatment with immunosuppressants
* previous treatment with corticoid (patient weaned for 3 months before inclusion)
* previous treatment with antimalarial drugs (HCQ/CQ) (patient must have been off plaquenil for at least 12 months)
* treatment with citalopram, escitalopram, hydroxyzin, domperidone and piperaquine
* known hypersensitivity or intolerance to HCQ/CQ or 4-aminoquinoline derivatives and prednisone
* heart rhythm disorders on EKG (QT prolongation) (except atrial fibrillations)
* severe ophthalmological impairment or ophthalmological impairment that does not allow ophthalmic monitoring; previous history of maculopathy or retinopathy
* end-stage lung, liver, cardiac, or renal disease
* sarcoidosis with central nervous system involvement
* cardiac sarcoidosis
* clinical evidence of active infection (including infection with herpes virus and varicella-zoster virus) or severe/unstabilized comorbidity (e.g. moderate to severe heart failure) or unstabilized psychosis
* chronic viral (HIV or HBV) infection
* untreated latent/active tuberculosis
* pregnancy or lactation (βHCG will be test by blood analysis at inclusion)
* concurrent vaccination with live vaccines during therapy
* inability to understand information about the protocol and to sign informed consent or not suitable candidate to comply with the requirements of this study
* patient participating in other interventional research
* persons under court protection
* Use of effective contraception for the duration of the study . (Contraception is considered effective when it consists of one of the following: use of a male condom during all sexual activity and/or efficient oral hormonal contraception (better considered combined contraception) and/or an intrauterine device (IUD) and/or hormone-releasing intrauterine system (IUS) and/or history of bilateral tubal ligation and/or history of vasectomy, provided the male partner is the trial participant's only sexual partner and/or sexual abstinence)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de Médecine Interne Infectiologie Aïgue Polyvalente- Hôpital Henri Duffaud

Avignon, , France

Site Status RECRUITING